Akebia Therapeutics, Inc. (AKBA)

NASDAQ: AKBA · IEX Real-Time Price · USD
0.316
-0.014 (-4.18%)
At close: Sep 30, 2022 4:00 PM
0.320
+0.004 (1.20%)
After-hours: Sep 30, 2022 6:47 PM EDT
-4.18%
Market Cap 58.13M
Revenue (ttm) 296.82M
Net Income (ttm) -163.37M
Shares Out 183.85M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,017,343
Open 0.322
Previous Close 0.330
Day's Range 0.300 - 0.329
52-Week Range 0.300 - 3.350
Beta 1.49
Analysts Sell
Price Target 1.66 (+425.0%)
Earnings Date Nov 2, 2022

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; an... [Read more...]

Industry Biotechnology
IPO Date Mar 20, 2014
CEO John Butler
Employees 426
Stock Exchange NASDAQ
Ticker Symbol AKBA
Full Company Profile

Financial Performance

In 2021, AKBA's revenue was $213.58 million, a decrease of -27.68% compared to the previous year's $295.31 million. Losses were -$282.84 million, -26.24% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for AKBA stock is "Sell." The 12-month stock price forecast is 1.66, which is an increase of 424.98% from the latest price.

Price Target
$1.66
(424.98% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , Sept. 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted ...

1 month ago - PRNewsWire

Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

1 month ago - PRNewsWire

Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Akebia to host conference call on August 4 at 4:30 p.m. ET Reported net Auryxia® (ferric citrate) product revenue of $43.7M, a 32.4% increase over Q2 2021 Increased 2022 net Auryxia product revenue guid...

1 month ago - PRNewsWire

Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for t...

CAMBRIDGE, Mass. , Aug. 4, 2022 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...

1 month ago - PRNewsWire

Akebia Therapeutics to Report Second Quarter Financial Results

Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to bette...

2 months ago - PRNewsWire

Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. The post Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

3 months ago - InvestorPlace

Akebia Therapeutics And 20 Stocks Moving Premarket

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.

3 months ago - Benzinga

Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday

Some of the stocks that may grab investor focus today are: Micron Technology Inc (NASDAQ: MU) reported upbeat financial results for its third quarter, but issued weak guidance for its fourth quarter. Mi...

Other symbols: MUACCDCOSTHI
3 months ago - Benzinga

Why Akebia Therapeutics Stock Is Soaring After Hours

Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with ...

3 months ago - Benzinga

Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countrie...

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia Akebia to assume responsibility for regulatory review processes previously led by Otsuka CAMBRIDGE, Mass. ,...

3 months ago - PRNewsWire

Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News

AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback. The post Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News...

3 months ago - InvestorPlace

Akebia Therapeutics to Present at Jefferies Healthcare Conference

CAMBRIDGE, Mass. , June 3, 2022  /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today an...

3 months ago - PRNewsWire

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass. , May 19, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ann...

4 months ago - PRNewsWire

Why Are Akebia Therapeutics Shares Falling Today?

Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on ...

4 months ago - Benzinga

AKBA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counse...

New York, New York--(Newsfile Corp. - May 13, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between Jun...

4 months ago - Newsfile Corp

AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead Plaintiff Deadline of May 13, 2022

NEW YORK , May 13, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA). To rece...

4 months ago - PRNewsWire

AKBA LAWSUIT ALERT: Levi & Korsinsky Notifies Akebia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcom...

NEW YORK , May 12, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsuit. CLASS DEFIN...

4 months ago - PRNewsWire

AKBA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Akebia Therapeutic...

New York, New York--(Newsfile Corp. - May 11, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Akebia Therapeutics, ...

4 months ago - Newsfile Corp

AKBA FINAL DEADLINE FRIDAY: GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Akebia Therapeutics, Inc. Investors with Lo...

New York, New York--(Newsfile Corp. - May 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between Jun...

4 months ago - Newsfile Corp

AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behal...

New York, New York--(Newsfile Corp. - May 11, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alle...

4 months ago - Newsfile Corp

Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action Deadline: Ma...

New York, New York--(Newsfile Corp. - May 11, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the ...

4 months ago - Newsfile Corp

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit an...

NEW YORK , May 11, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Akebia Therapeutics, Inc.. Shareholders who purchased shares of AKBA during the class period lis...

4 months ago - PRNewsWire

Akebia Class Action: Levi & Korsinsky Reminds Akebia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit...

New York, New York--(Newsfile Corp. - May 10, 2022) - Levi & Korsinsky, LLP notifies investors in Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) of a class action securities lawsui...

4 months ago - Newsfile Corp

AKBA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behal...

NEW YORK , May 10, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) alleging that the ...

4 months ago - PRNewsWire